Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD140 CAR-T in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT06655519Phase 1Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2024
- Primary completion
- Jul 2028
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of RD140 in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by Peking University People's Hospital. Primary endpoint: Adverse Events at 2 years. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
RD140
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT06655519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655519.